Vitamin K antagonists in children with heart disease: Height and VKORC1 genotype are the main determinants of the warfarin dose requirement

Blood

Volumn 119, Issue 3, 2012, Pages 861-867

  Moreau, Caroline ^a,b   Bajolle, Fanny ^a   Siguret, Virginie ^a,b   Lasne, Dominique ^a,c   Golmard, Jean Louis ^d   Elie, Caroline ^a   Beaune, Philippe ^a,b   Cheurfi, Radhia ^a   Bonnet, Damien ^a   Loriot, Marie Anne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Laboratoire Central d'Hematologie   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; FLUINDIONE; OXIDOREDUCTASE; SPIRONOLACTONE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ADOLESCENT; ADULT; AGE; ALLELE; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ANEURYSM; CYANOTIC HEART DISEASE; DOSE CALCULATION; FEMALE; GENOTYPE; HEART ARRHYTHMIA; HEART DISEASE; HETEROZYGOTE; HISTIOCYTOSIS; HOMOZYGOTE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUPUS VULGARIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SEX DIFFERENCE; SICKLE CELL ANEMIA; WILD TYPE;

EID: 84856072430     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365502     Document Type: Article

References (36)

1. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6 Suppl):887S-968S. (Pubitemid 351892979)
2. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999;94(9):3007-3014. (Pubitemid 29512704)
3. Monagle P, Newall F, Campbell J. Anticoagulation in neonates and children: Pitfalls and dilemmas. Blood Rev. 2010;24(4-5):151-162.
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22): 2285-2293. (Pubitemid 40740552)
5. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anti-coagulant effect of warfarin. Blood. 2005;105(2): 645-649. (Pubitemid 40070748)
6. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-2333. (Pubitemid 41510803)
7. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.
8. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358(10):999-1008. (Pubitemid 351347099)
9. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784-792.
10. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106-4112.
11. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112(4):1022-1027.
12. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
13. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
14. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009;113(17): 3925-3930.
15. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics. 2011;12(1):15-25.
16. Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005;3(8):1873-1878. (Pubitemid 41716574)
17. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106(1):135-140. (Pubitemid 40967184)
18. Becquemont L. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol. 2008; 64(10):953-960.
19. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements- a systematic review and metaanalysis. Eur J Clin Pharmacol. 2009;65(4):365-375.
20. Pérez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113(20):4977-4979.
21. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. 2008;84(3):332-339.
22. Wells PS, Majeed H, Kassem S, et al. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res. 2010;125(6):e259-e264.
23. Carlquist JF, Horne BD, Mower C, et al. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis. 2010;30(3):358-364.
24. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68(5): 541-555.
25. Kosaki K, Yamaghishi C, Sato R, et al. 1173C〉T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr Cardiol. 2006;27(6): 685-688. (Pubitemid 44915404)
26. Ruud E, Holmstrom H, Bergan S, Wesenberg F. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer. 2008;50(3):710-713. (Pubitemid 351155871)
27. Nowak-Göttl U, Dietrich K, Schaffranek D, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116(26):6101-6105.
28. Goldenberg NA, Crowther MA. The "age" of understanding VKA dose. Blood. 2010;116(26): 5789-5790.
29. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-239. (Pubitemid 23069000)
30. Smadja DM, Loriot MA, Hindorff LA, Mellottee L, Gaussem P, Emmerich J. No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease. Thromb Haemost. 2008;99(5):970-972. (Pubitemid 351705321)
31. Piquet P, Losay J, Doubine S. Acenocoumarol (Sintrom) and fluindione (Previscan) in pediatrics after cardiac surgical procedures [article in French]. Arch Pediatr. 2002;9(11):1137-1144. (Pubitemid 35429292)
32. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006;79(4): 291-302.
33. Kato Y, Ichida F, Saito K, et al. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet. 2011;26(3):295-299.
34. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20(3):243-247. (Pubitemid 28248841)
35. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010;87(1):57-64.
36. Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol. 2010;17(4):208-213.